Notice2023-24506
Determination That FORADIL (Formoterol Fumarate) Inhalation Powder, 0.012 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
November 6, 2023
Issuing agencies
Health and Human Services DepartmentFood and Drug Administration
Abstract
The Food and Drug Administration (FDA, the Agency, or we) has determined that FORADIL (formoterol fumarate) inhalation powder, 0.012 milligrams (mg)/inhalation (inh), was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for formoterol fumarate inhalation powder, 0.012 mg/inh, if all other legal and regulatory requirements are met.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 213 (Monday, November 6, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 213 (Monday, November 6, 2023)]
[Notices]
[Pages 76218-76219]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-24506]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2023-P-2536]
Determination That FORADIL (Formoterol Fumarate) Inhalation
Powder, 0.012 Milligrams, Was Not Withdrawn From Sale for Reasons of
Safety or Effectiveness
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA, the Agency, or we) has
determined that FORADIL (formoterol fumarate) inhalation powder, 0.012
milligrams (mg)/inhalation (inh), was not withdrawn from sale for
reasons of safety or effectiveness. This determination will allow FDA
to approve abbreviated new drug applications (ANDAs) for formoterol
fumarate inhalation powder, 0.012 mg/inh, if all other legal and
regulatory requirements are met.
FOR FURTHER INFORMATION CONTACT: Joe Thomas, Center for Drug Evaluation
and Research, Food and Drug Administration, 10903 New Hampshire Ave.,
Bldg. 51, Rm. 6217, Silver Spring, MD 20993-0002, 202-815-5571,
<a href="/cdn-cgi/l/email-protection#8fe5e0fceaffe7a1fbe7e0e2eefcbecfe9ebeea1e7e7fca1e8e0f9"><span class="__cf_email__" data-cfemail="751f1a0610051d5b011d1a18140644351311145b1d1d065b121a03">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: Section 505(j) of the Federal Food, Drug,
and Cosmetic Act (FD&C Act) (21 U.S.C. 355(j)) allows the submission of
an ANDA to market a generic version of a previously approved drug
product. To obtain approval, the ANDA applicant must show, among other
things, that the generic drug product: (1) has the same active
ingredient(s), dosage form, route of administration, strength,
conditions of use, and (with certain exceptions) labeling as the listed
drug, which is a version of the drug that was previously approved; and
(2) is bioequivalent to the listed drug. ANDA applicants do not have to
repeat the extensive clinical testing otherwise necessary to gain
approval of a new drug application (NDA).
Section 505(j)(7) of the FD&C Act requires FDA to publish a list of
all
[[Page 76219]]
approved drugs. FDA publishes this list as part of the ``Approved Drug
Products With Therapeutic Equivalence Evaluations,'' which is known
generally as the ``Orange Book.'' Under FDA regulations, drugs are
removed from the list if the Agency withdraws or suspends approval of
the drug's NDA or ANDA for reasons of safety or effectiveness or if FDA
determines that the listed drug was withdrawn from sale for reasons of
safety or effectiveness (21 CFR 314.162).
A person may petition the Agency to determine, or the Agency may
determine on its own initiative, whether a listed drug was withdrawn
from sale for reasons of safety or effectiveness. This determination
may be made at any time after the drug has been withdrawn from sale,
but must be made prior to approving an ANDA that refers to the listed
drug (Sec. 314.161 (21 CFR 314.161)). FDA may not approve an ANDA that
does not refer to a listed drug.
FORADIL (formoterol fumarate) inhalation powder, 0.012 mg/inh, is
the subject of NDA 020831, held by Novartis Pharmaceuticals Corp., and
initially approved on February 16, 2001. FORADIL is indicated for
treatment of asthma in patients 5 years of age and older as an add-on
to a long-term asthma control medication such as an inhaled
corticosteroid; prevention of exercise-induced bronchospasm (EIB) in
patients 5 years of age and older; and maintenance treatment of
bronchoconstriction in patients with chronic obstructive pulmonary
disease.
In a letter dated September 30, 2015, Novartis Pharmaceuticals
Corp. notified FDA that FORADIL (formoterol fumarate) inhalation
powder, 0.012 mg/inh, was being discontinued, and FDA moved the drug
product to the ``Discontinued Drug Product List'' section of the Orange
Book. In the Federal Register of June 21, 2018 (83 FR 28856), FDA
announced that it was withdrawing approval of NDA 020831, effective
July 23, 2018.
K&L Gates LLP submitted a citizen petition dated June 21, 2023
(Docket No. FDA-2023-P-2536), under 21 CFR 10.30, requesting that the
Agency determine whether FORADIL (formoterol fumarate) inhalation
powder, 0.012 mg/inh, was withdrawn from sale for reasons of safety or
effectiveness.
After considering the citizen petition and reviewing Agency records
and based on the information we have at this time, FDA has determined
under Sec. 314.161 that FORADIL (formoterol fumarate) inhalation
powder, 0.012 mg/inh, was not withdrawn for reasons of safety or
effectiveness. The petitioner has identified no data or other
information suggesting that FORADIL (formoterol fumarate) inhalation
powder, 0.012 mg/inh, was withdrawn for reasons of safety or
effectiveness. We have carefully reviewed our files for records
concerning the withdrawal of FORADIL (formoterol fumarate) inhalation
powder, 0.012 mg/inh, from sale. We have also independently evaluated
relevant literature and data for possible postmarketing adverse events.
We have reviewed the available evidence and determined that this drug
product was not withdrawn from sale for reasons of safety or
effectiveness.
Accordingly, the Agency will continue to list FORADIL (formoterol
fumarate) inhalation powder, 0.012 mg/inh, in the ``Discontinued Drug
Product List'' section of the Orange Book. The ``Discontinued Drug
Product List'' delineates, among other items, drug products that have
been discontinued from marketing for reasons other than safety or
effectiveness. FDA will not begin procedures to withdraw approval of
approved ANDAs that refer to this drug product. Additional ANDAs for
this drug product may also be approved by the Agency as long as they
meet all other legal and regulatory requirements for the approval of
ANDAs. If FDA determines that labeling for this drug product should be
revised to meet current standards, the Agency will advise ANDA
applicants to submit such labeling.
Dated: November 1, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-24506 Filed 11-3-23; 8:45 am]
BILLING CODE 4164-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on November 6, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.